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Introduction {#nan12498-sec-0005}
============

Juvenile dermatomyositis (JDM) is a rare chronic inflammatory myopathy of childhood, with primary symptoms including symmetrical, proximal muscle weakness and typical skin rashes including Gottron\'s papules and heliotrope rash. Activated type I interferon (IFN) pathway has been shown to be a key factor in pathogenesis of JDM and adult DM [1](#nan12498-bib-0001){ref-type="ref"}, [2](#nan12498-bib-0002){ref-type="ref"}, [3](#nan12498-bib-0003){ref-type="ref"}. Myxovirus‐resistance protein A (MxA) which is one of the type I IFN‐induced proteins, and is specifically regulated by the type I IFN pathway [4](#nan12498-bib-0004){ref-type="ref"}, [5](#nan12498-bib-0005){ref-type="ref"}. During the last decade, type I IFN gene expression in blood has been shown to correlate with disease activity and muscle involvement in DM patients [6](#nan12498-bib-0006){ref-type="ref"}, [7](#nan12498-bib-0007){ref-type="ref"}. Also, MxA expression in muscle of DM patients has been previously demonstrated [2](#nan12498-bib-0002){ref-type="ref"}, [8](#nan12498-bib-0008){ref-type="ref"}. Moreover, a previous report has shown that the expression of type I IFN signature genes in muscle tissues of adult DM patients was stronger than in JDM patients except for MX1 gene [9](#nan12498-bib-0009){ref-type="ref"}. Since muscle is the major target of inflammation in JDM, the presence of MxA protein in muscle biopsies could be of relevance to direct mechanisms of tissue injury. This study aimed to evaluate the relationship between expression of MxA protein on muscle biopsies by immunohistochemistry (IHC) and disease activity in JDM patients. Moreover, myositis‐specific autoantibodies (MSA) which are exclusively present in myositis patients, have been shown to help describe distinct groups of patients with similar clinical characteristics, treatment outcome and prognosis [10](#nan12498-bib-0010){ref-type="ref"}, [11](#nan12498-bib-0011){ref-type="ref"}, [12](#nan12498-bib-0012){ref-type="ref"}, [13](#nan12498-bib-0013){ref-type="ref"}, [14](#nan12498-bib-0014){ref-type="ref"}, [15](#nan12498-bib-0015){ref-type="ref"}. A secondary aim of this study was to investigate whether the expression of MxA is related with MSA status in JDM patients.

Materials and methods {#nan12498-sec-0006}
=====================

Patients, clinical features and laboratory data {#nan12498-sec-0007}
-----------------------------------------------

This study included clinical data and muscle biopsy samples from 103 patients with definite or probable JDM [16](#nan12498-bib-0016){ref-type="ref"}, [17](#nan12498-bib-0017){ref-type="ref"} who were already recruited to the Juvenile Dermatomyositis Cohort and Biomarker Study (JDCBS) [18](#nan12498-bib-0018){ref-type="ref"}. Written informed consent and age appropriate assent were received from parents and patients respectively. The study was approved by the Northern & Yorkshire Medical Research and Ethics Committee (MREC), UK. Patient data were obtained through the JDCBS database including age at disease onset, gender, time between onset and biopsy date, and whether any medication was received before muscle biopsy. Clinical features at presentation were collected including the presence of calcinosis, nail fold capillary abnormality, pulmonary involvement, Childhood Myositis Assessment Scale (CMAS) [19](#nan12498-bib-0019){ref-type="ref"}, Manual Muscle Testing of Eight Muscles (MMT8) [20](#nan12498-bib-0020){ref-type="ref"}, and the physician\'s global assessment (PGA). The CMAS has a range from 0 to 52, with high scores corresponding to no physical disability. The MMT8 ranges from 0 to 80, with high scores indicating no muscle weakness. The PGA is the assessment of the patient\'s overall disease activity scored by a physician at the time of assessment, ranging from 0 to 10 (high scores corresponding to maximal disease). Serum levels of muscle enzymes including creatine kinase (CK), lactate dehydrogenase (LDH) and aldolase were routinely collected at the first visit.

Autoantibody detection {#nan12498-sec-0008}
----------------------

Autoantibodies were screened for by radio‐immunoprecipitation as described previously [21](#nan12498-bib-0021){ref-type="ref"}. Anti‐nuclear matrix protein 2 (NXP‐2) and anti‐melanoma differentiation‐associated gene 5 (MDA5) antibodies were subsequently confirmed by enzyme‐linked immunosorbent assay [11](#nan12498-bib-0011){ref-type="ref"}, [12](#nan12498-bib-0012){ref-type="ref"}. We included patients with MSA and no‐detectable autoantibodies during the analyses in order to assess the relationships between MSA status and MxA expression on JDM muscle specimens.

Muscle biopsy tissues and scoring data {#nan12498-sec-0009}
--------------------------------------

Open biopsy material obtained from vastus lateralis of 103 patients was analysed. All muscle biopsy samples were snap‐frozen within 1 h of operation and stored at −80°C. Cryostat sections (7 μm) were cut, air‐dried overnight, fixed with acetone, and stored at −80°C until used. All cases had been stained and scored according to a standardized scoring system as described [22](#nan12498-bib-0022){ref-type="ref"}, [23](#nan12498-bib-0023){ref-type="ref"}. The scoring tool consists of four domains: inflammatory, vascular, muscle fibre and connective tissue domain. Total biopsy score is the sum of all four domains (range 0--27; high scores indicate severe pathological abnormalities). This tool also includes a histopathologists\' visual analogue score (hVAS) which assessed the overall severity (range 0--10; high scores indicate worse pathology). A set of normal muscle biopsies from subjects with no muscle disease were analysed in parallel for comparison [24](#nan12498-bib-0024){ref-type="ref"}. Biopsy scores and clinical and serology data for most of the patients reported in the present study overlap with those previously reported by our group [25](#nan12498-bib-0025){ref-type="ref"}. The MxA staining data have not yet been reported.

Immunohistochemical staining of MxA protein and microscopic evaluation {#nan12498-sec-0010}
----------------------------------------------------------------------

A total of 103 patients had muscle biopsy tissues available which were manually stained for MxA by IHC staining. All specimens were also stained and scored using the standardized score tool for JDM histopathology previously reported to maintain consistency [22](#nan12498-bib-0022){ref-type="ref"}. Eighteen control muscle biopsy samples from subjects with no muscle disease and no abnormality at light microscopy were included for analysis in comparison. The primary antibodies used to detect MxA protein were mouse anti‐human anti‐MxA monoclonal antibodies (clone: M143, 1:400 dilution; Merck, Kenilworth, NJ, USA) Horseradish peroxidase and DAB (Dako, Cambridgeshire, UK) were used as secondary antibodies and the chromogen respectively. Fiji imaging software (Bethesda, Maryland, USA) was used to process the images. The expression of MxA in muscle fibres was scored semi‐quantitatively by two independent investigators including a senior neurohistopathologist who were blinded to patients\' clinical features and laboratory data. The scores ranged from 0 to 3 (0 = no MxA staining; 1 = weak; 2 = moderate; 3 = strong). In each specimen, the patterns of MxA staining were evaluated as either perifascicular, nonperifascicular or both. Perifascicular pattern was defined by the presence of brown staining at the peripheral area of muscle fascicles and the definition of nonperifascicular pattern was patchy or diffuse staining in a section.

Statistical analyses {#nan12498-sec-0011}
--------------------

Data were analysed using SPSS Statistics for Windows (Version 23.0. Armonk, NY, USA; IBM Corporation). Descriptive statistics of baseline characteristics were summarized using median and interquartile range for numeric variables and percentages for categorical variables. Differences in CMAS scores, MMT8, PGA and serum levels of muscle enzymes between different MxA scoring data were tested by Kruskal--Wallis analysis of variance. *Post hoc* tests were performed to explore significant differences between pairs of MxA scoring data and *P*‐values were adjusted by using Bonferroni\'s correction for multiple comparisons. Fisher\'s exact test was used to examine differences of MxA scoring data in different MSA subgroups. To estimate the association between the extent of MxA expression on muscle fibres and disease activity, multiple linear regression analysis was performed. The strength of the association from the regression analysis was described by the standardized coefficient (β). The interobserver variability was analysed using Bland--Altman method which the mean difference (−0.05) and 95% limits of agreement (0.048, −0.148) were calculated and confirmed high agreement. *P*‐values \<0.05 were considered statistically significant.

Results {#nan12498-sec-0012}
=======

Demographic data, clinical features and laboratory data {#nan12498-sec-0013}
-------------------------------------------------------

Demographic data and clinical characteristics of all 103 JDM patients are summarized in Table [1](#nan12498-tbl-0001){ref-type="table"}. There was a female predominance (64.1%). Median age at disease onset was 6.3 (0.5--15.9) years and median duration from disease onset to muscle biopsy was 3.8 (2.6--8.7) months. Patients represented a range of disease severities. About 9% and 11% of patients had received corticosteroids and methotrexate at time of muscle biopsy respectively. Since immunosuppressive drugs, such as corticosteroids and methotrexate, have been shown to have an effect on the type 1 IFN pathway [26](#nan12498-bib-0026){ref-type="ref"}, we compared patients who had received no drugs prior to biopsy to those who had received immunosuppressive drugs: there were no differences in clinical features, laboratory data and MxA scoring data between the two groups (Table [S1](#nan12498-sup-0001){ref-type="supplementary-material"}). Thus, all 103 patients were included in the study. The three most prevalent MSAs detected in these patients were anti‐transcriptional intermediary factor 1‐gamma (19.8%), anti‐NXP‐2 (18.8%) and anti‐MDA5 (11.9%) which was consistent with previous reports [10](#nan12498-bib-0010){ref-type="ref"}, [27](#nan12498-bib-0027){ref-type="ref"}.

###### 

Demographic data and clinical features of 103 juvenile dermatomyositis patients at initial presentation

  Characteristics                                         Median (IQR)[a](#nan12498-note-0002){ref-type="fn"}
  ------------------------------------------------------- -----------------------------------------------------
  Female, *n* (%)                                         66 (64.1)
  Age at disease onset, years                             6.3 (0.5--15.9)
  Duration from disease onset to first visit, months      4.3 (2.7--9.8)
  Time from disease onset to muscle biopsy, months        3.8 (2.6--8.7)
  Time from first visit to muscle biopsy, months          0.67 (0.35--0.86)
  On immunosuppressive drugs at time of biopsy, *n* (%)   
  Corticosteroids                                         9 (8.7)
  Methotrexate                                            11 (10.7)
  CMAS (*n* = 90)                                         28.5 (16--45)
  MMT8 (*n* = 62)                                         54 (35--71)
  PGA (*n* = 72)                                          5.95 (3.5--7.7)
  CK, units/l (*n* = 96)                                  367 (77--2146.5)
  Myositis autoantibodies, *n* (%) (*n* = 101)            
  MDA5                                                    12 (11.9)
  NXP‐2                                                   19 (18.8)
  Mi2                                                     5 (5)
  TIF1γ                                                   20 (19.8)
  No detectable                                           19 (18.8)

IQR, interquartile range; CK, creatine kinase; CMAS, Childhood Myositis Assessment Scale (scores 0--52); MDA5, melanoma differentiation‐associated gene 5; MMT8, Manual Muscle Testing of Eight Muscles (scores 0--80); NXP‐2, nuclear matrix protein 2; PGA, physician global assessment (scores 0--10); TIF1γ, transcriptional intermediary factor 1‐gamma.

Data are presented as median (IQR) if not stated otherwise.
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Expression of MxA protein in muscle fibres from JDM patients {#nan12498-sec-0014}
------------------------------------------------------------

Representative immunohistochemical staining of MxA protein expression in muscle fibres from JDM patients is shown in Figure [1](#nan12498-fig-0001){ref-type="fig"} **A**. Expression of MxA protein on muscle fibres of JDM samples was identified in 63 patients (61.2%) (Figure [1](#nan12498-fig-0001){ref-type="fig"} **B**), whereas 82.5% of JDM patients had diffuse staining on capillaries. Moreover, in 18 normal control muscle biopsies, 67% had capillary staining of MxA while there was no MxA protein expression on muscle fibres in any normal specimens (data not shown). Among JDM patients with positive MxA staining on muscle fibres, more than half (57.1%) had strong MxA expression. The distribution of MxA expression was observed in both perifascicular (46%) and nonperifascicular (53%) patterns.

![Immunohistochemical staining of myxovirus‐resistance protein A (MxA) in juvenile dermatomyositis (JDM) muscle tissues. (**A**) Representative immunohistochemical staining of MxA in JDM biopsies. (a1) Negative MxA staining in muscle fibres. (a2) Perifascicular MxA expression with score of 1. (a3) Nonperifascicular MxA expression with score of 1. (a4) Nonperifascicular and perifascicular MxA expression with score of 2. (a5) Perifascicular MxA expression with score of 2. (a6) Strong nonperifascicular MxA expression with score of 3. Original magnifications: × 20 (a1); × 10 (a2--6). (**B**) Percentage of patients in different degrees of MxA expression in 103 JDM patients. MxA total score was analysed in a whole image of specimens. In each specimen, the patterns of MxA staining were evaluated as either perifascicular, nonperifascicular or both.](NAN-45-410-g001){#nan12498-fig-0001}

Increased MxA expression on muscle fibres was associated with increased muscular disease activity in JDM {#nan12498-sec-0015}
--------------------------------------------------------------------------------------------------------

The distribution of different MxA scores did not differ according to age at disease onset, gender or clinical features at first presentation, such as, the presence of calcinosis, nail fold capillary changes or PGA (Table [S2](#nan12498-sup-0001){ref-type="supplementary-material"}). However, there was a significant association between MxA scores and CMAS, and MMT8 (*P* = 0.002 and 0.026, respectively). The *post hoc* analysis showed the significant differences in CMAS score between patients with MxA scores of 0 and 2 (*P* = 0.044), and MxA scores of 0 and 3 (*P* = 0.001) (Figure [2](#nan12498-fig-0002){ref-type="fig"} **A**). The median CMAS score in the strong MxA expression group was 19 (9--46), whereas in the group with no MxA expression, the CMAS score was 41.5 (29--52). Similarly, MMT8 scores differed significantly between patients with MxA scores of 0 and 3 (*P* = 0.013) (Figure [2](#nan12498-fig-0002){ref-type="fig"} **B**). Since there was evidence of a significant association with time from disease onset to muscle biopsy (*P* = 0.046), multiple linear regression analysis was performed in order to confirm the associations between MxA scoring data and CMAS scores, and MMT8 after adjustment for any confounding effects of time from disease onset to biopsy. From this analysis, expression of MxA protein was found to be significantly associated with CMAS scores and MMT8 at disease onset (Figure [2](#nan12498-fig-0002){ref-type="fig"} **C**,**D**). Thus, patients with MxA scores of 3 had on the average 16 units lower scores CMAS scores when compared to patients with MxA scores of 0 and patients with MxA scores of 1 had on average 7 units lower CMAS scores when compared to patients with MxA scores of 0. Similarly, patients with MxA scores of 3 were associated with an average of 17 units lower MMT8 scores than patients with MxA scores of 0.

![Association between muscular disease activity and relative MxA protein expression on JDM muscle samples. Distribution of (**A**) CMAS score (*P* = 0.002), (**B**) MMT8 (*P* = 0.026) across MxA scoring data. Kruskal--Wallis [anova]{.smallcaps} was tested to analyse the difference in the distribution. Horizontal bars show median values. *Post hoc* comparisons were automatically performed when the *P*‐value was statistically significant. Forest plots of linear regression‐estimated coefficients for (**C**) CMAS and (**D**) MMT8 showing significant relationships between MxA protein expression on JDM muscles and muscular disease activity. CMAS, Childhood Myositis Assessment Scale; JDM, juvenile dermatomyositis; MMT8, Manual Muscle Testing of Eight Muscles; MxA, myxovirus resistance protein A.](NAN-45-410-g002){#nan12498-fig-0002}

Laboratory markers of disease severity, such as CK and LDH were also investigated for the relationship of MxA scoring data. However, serum levels of muscle enzymes were not associated with the expression of MxA protein on JDM muscle samples (Table [S2](#nan12498-sup-0001){ref-type="supplementary-material"}).

NXP‐2 and MDA5 autoantibodies had differing levels of MxA expression on JDM muscle fibres {#nan12498-sec-0016}
-----------------------------------------------------------------------------------------

The extent of MxA expression differed significantly according to MSA subgroups (*P* = 0.002). Patients with positive NXP‐2 autoantibodies tended to have strong MxA expression, whereas anti‐MDA5 positive patients had no or weak MxA expression on muscle biopsies (Figure [3](#nan12498-fig-0003){ref-type="fig"}). There was no clear trend in patients with other MSA subtypes or no detectable autoantibodies. According to the distribution patterns of MxA staining, there was no clear association between different MSA subgroups and characteristic MxA stains in JDM muscle samples (*P* = 0.084, Table [S3](#nan12498-sup-0001){ref-type="supplementary-material"}). However, this borderline insignificant finding needs to be further investigated in a larger study.

![Distributions of MxA protein expression on JDM muscle samples across MSA subgroups. Fisher\'s exact test was done to analyse the difference in the distributions and *P‐*value was 0.002. JDM, juvenile dermatomyositis; MDA5, melanoma differentiation‐associated gene 5; MSA, myositis‐specific autoantibody; MxA, myxovirus‐resistance protein A; NXP‐2, nuclear matrix protein 2; TIF1γ, transcriptional intermediary factor 1‐gamma.](NAN-45-410-g003){#nan12498-fig-0003}

The expression of MxA protein on JDM muscle fibres was highly associated with scores of histopathological severity {#nan12498-sec-0017}
------------------------------------------------------------------------------------------------------------------

The levels of MxA expression on muscle samples had a positive correlation with several features of the biopsy scoring tool including the inflammatory domain and muscle fibre domains, total biopsy scores and hVAS (Figure [4](#nan12498-fig-0004){ref-type="fig"} **A**--**D**). There were significant statistical differences in those biopsy domains between patients with MxA score of 0 and 3. Interestingly, patients with MxA scores of 0 and 1 tended to have wider range of scores in inflammatory domain, and total biopsy score when compared to patients with MxA scores of 2 and 3.

![Relationships between MxA scoring data and different domains in a biopsy scoring tool. Distribution of scores in (**A**) inflammatory domain (*P*‐value from Kruskal--Wallis [anova]{.smallcaps} was 0.001), (**B**) muscle fibre domain (*P*‐value was 0.014), in a biopsy scoring tool, (**C**) total biopsy score (*P*‐value was 0.002), (**D**) hVAS (*P*‐value was 0.004) in different MxA protein expression on JDM muscle samples. Horizontal bars show median values. *Post hoc* comparisons were automatically performed when the *P*‐value from Kruskal--Wallis [anova]{.smallcaps} was statistically significant. hVAS, histopathologist\'s visual analogue scale global pathology score; IFN, interferon; JDM, juvenile dermatomyositis; MxA, myxovirus‐resistance protein A.](NAN-45-410-g004){#nan12498-fig-0004}

Discussion {#nan12498-sec-0018}
==========

To our knowledge, this is the first study to demonstrate MxA protein expression on muscle fibres in a large cohort of JDM muscle biopsies (*n* = 103). Assessment muscle biopsies from JDM patients has the potential to reveal pathophysiology of JDM. The expression of MxA protein on muscle biopsies detected by immunohistochemical staining has been recently demonstrated and a role as a marker for diagnosis of DM suggested, in a study of 34 cases of DM (of which 10 were JDM patients) [28](#nan12498-bib-0028){ref-type="ref"}. Although the sample size in the previous study was limited, there was about 90% of JDM patients who had positive MxA staining in muscle fibres. The percentages of positive MxA staining in JDM in the previous study is higher than in this study which was about 61% could be explained by the different classification criteria for including of participants and different MxA clones for IHC detection. Further possible explanations would be the differences in median age at disease onset, duration from disease onset to muscle biopsy and the location of muscle the biopsy was taken from. However, these details were not provided in the previous study. Building upon this, our study has demonstrated that MxA expression may also be used as a histological biomarker for JDM disease activity within the muscle tissue. We revealed the strong association between type I IFN response in muscle tissues as assessed by immunohistochemical staining of MxA protein and muscle disease activity in JDM patients. In patients with a high degree of muscle disease severity, MxA protein expression on muscle fibres was found at elevated levels. However, no association was identified between degree of MxA expression on muscle tissue and serum levels of muscle enzymes CK and LDH. These data support that serum levels of muscle enzymes do not correlate well with JDM disease activity as previously reported [29](#nan12498-bib-0029){ref-type="ref"}, [30](#nan12498-bib-0030){ref-type="ref"}. Previous studies have used gene expression profiling to demonstrate correlation between type I IFN response in blood and muscle disease activity in adult DM and JDM [6](#nan12498-bib-0006){ref-type="ref"}, [7](#nan12498-bib-0007){ref-type="ref"}, [26](#nan12498-bib-0026){ref-type="ref"}, [31](#nan12498-bib-0031){ref-type="ref"}. Muscle from adult DM patients showed significant higher levels of MxA expression than in blood [26](#nan12498-bib-0026){ref-type="ref"}. This was explained by the hypothesis that some infiltrating inflammatory cells in muscle tissues themselves can express MxA. However, in our study, we measured degrees of MxA protein expression only in muscle fibres, not in inflammatory cells.

Additionally, this is the first study revealing the association of level of MxA protein expression on muscle fibres and MSA subtype specificities in JDM patients. There are few studies showing the correlation between specificities of myositis autoantibodies and IFN pathway activation in blood. A previous study in adult patients showed a significantly higher whole blood IFN score in patients with idiopathic inflammatory myopathies who had anti‐Jo1, anti‐Ro60 and anti‐U1RNP autoantibodies when compared to patients with positive anti‐Ro52 and anti‐PM/Scl [32](#nan12498-bib-0032){ref-type="ref"}. However, no data demonstrates the association between other major MSA and levels of IFN pathway activation in JDM patients. Moreover, there are limited studies describing characteristics of muscle histopathology and degrees of muscular inflammation in distinct MSA subtypes. A recent study showed that anti‐NXP‐2 JDM cases had variable scores of histopathological severity [25](#nan12498-bib-0025){ref-type="ref"}, whereas a study of adult DM demonstrated that anti‐NXP‐2 patients had less muscle inflammation [33](#nan12498-bib-0033){ref-type="ref"}. In the present study, we observed that patients with NXP‐2 autoantibodies had greater degree of muscle inflammation since they had higher level of MxA expression on muscle fibres than other MSA subgroups. In contrast, there was no or low levels of MxA protein expression on muscle biopsies in patients with anti‐MDA5 autoantibodies. Previous studies also showed that anti‐MDA5 antibodies were associated with milder muscle disease activity and muscle pathology than patients with other MSA subgroups [12](#nan12498-bib-0012){ref-type="ref"}, [25](#nan12498-bib-0025){ref-type="ref"}. Also, adult patients with anti‐MDA5 autoantibodies did not have perifascicular atrophy which is one of the classic pathological features of DM [34](#nan12498-bib-0034){ref-type="ref"}, whereas about 58.3% of anti‐MDA5 positive patients in this study had perifascicular atrophy. This could be due to the different pathological findings between adult and paediatric patients. Moreover, a previous Japanese study showed that among muscle biopsies from three patients with anti‐MDA5 autoantibodies, none of the patients had perifascicular atrophy and two patients had MxA expression on muscle fibres [28](#nan12498-bib-0028){ref-type="ref"}. In this study, although sample size in this MSA subgroup was limited, about 33.3% of anti‐MDA5 autoantibodies positive patients demonstrated expression of MxA protein on muscle fibres. Another Japanese study demonstrated that anti‐MDA5 autoantibody positive DM patients had higher levels of serum IFN‐α than in those negative for anti‐MDA5 autoantibodies [35](#nan12498-bib-0035){ref-type="ref"}. These variable results may reflect genetic and environmental differences between anti‐MDA5 positive patients. It is known that the MDA5 positive patients typically have mild muscle disease and it is therefore possible that IFN inducible proteins mainly circulate in blood but are not highly expressed in muscles of patients with MDA5 autoantibodies. Moreover, some evidence suggests a possible protective mechanism through nitric oxide synthase 2 expression in skeletal muscle of anti‐MDA5 autoantibody positive patients [34](#nan12498-bib-0034){ref-type="ref"}. Thus, MDA5 positive patients have limited muscular involvement while they have more severe extramuscular manifestations, such as pulmonary involvement. These results confirm the divergent disease pathophysiology of JDM in different MSA positive groups. Our study showed strong correlations between the degree of MxA expression on muscle fibres and several domains in the JDM biopsy scoring tool [22](#nan12498-bib-0022){ref-type="ref"}. Interestingly, the distribution of scores in inflammatory domain and total biopsy scores in patients with no or weak MxA expression tended to have wider range of scores. This may suggest that muscle biopsy specimens with high MxA protein expression might provide more convincing information of muscle tissue injury.

In summary, in this study, we identified MxA protein expression in muscle fibres as a useful histological biomarker of JDM disease activity to supplement the assessment of IFN pathway activation and management of JDM patients. This could help with improving treatment outcome and minimizing comorbidities associated with treatment and disease in JDM patients. Moreover, we emphasize the association of different MSA subgroups in stimulation of the IFN type I pathway which involved in muscle damage in JDM and underscore the distinct pathophysiological pathways in different MSA status. This needs the careful phenotyping of JDM patients for tailored therapy for better outcome.
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